A Phase 2 study of DISC-3405 in Polycythemia Vera

Study Description

An Open-Label Study to Evaluate the Safety and Effectiveness of an Investigational Drug (DISC-3405) in Patients with Polycythemia Vera

Study Details

Registry ID:

NCT06985147

Conditions:

Polycythemia Vera (PV)

Phase:

Phase 2

Target Enrollment:

60 participants

Start Date:

August 12, 2025

Age Range:

18–999 years

Healthy Volunteers:

No

Study Locations (15 sites)

• Duke University
  Durham, North CarolinaUnited States, United States
• Mayo Clinic in Florida
  Jacksonville, FloridaUnited States, United States
• Atrium Health Wake Forest Baptist Medical Center
  Winston-Salem, North CarolinaUnited States, United States
• Atrium Health - Levine Cancer Center
  Charlotte, North CarolinaUnited States, United States
• Cleveland Clinic
  Cleveland, OhioUnited States, United States
• Ohio State University
  Columbus, OhioUnited States, United States
• Siteman Cancer Center - Washington University St. Louis
  St Louis, MissouriUnited States, United States
• MD Anderson Cancer Center
  Houston, TexasUnited States, United States
• Mayo Clinic in Minnesota
  Rochester, MinnesotaUnited States, United States
• Mayo Clinic in Arizona
  Phoenix, ArizonaUnited States, United States
• Keck Medicine of USC - Cancer Clinic- Newport Beach
  Newport Beach, CaliforniaUnited States, United States
• UCLA Health
  Los Angeles, CaliforniaUnited States, United States
• USC Norris Comprehensive Cancer Center
  Los Angeles, CaliforniaUnited States, United States
• Oregon Health & Science University
  Portland, OregonUnited States, United States
• University of Washington - Fred Hutchinson Cancer Research Center
  Seattle, WashingtonUnited States, United States

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →